APAC CRISPR Gene Detection and Diagnostics Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 144008
- Pages: 225
-
Format:
Short Description
Asia-Pacific CRISPR Gene Detection and Diagnostic Market, By Class (Class 1- Multiple Effector Proteins and Class 2 -Single CrRNA-Binding Protein), Products & Services (Products and Services), Application (Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications and Others), Workflow (Sample Preparation, Pre-Amplification, CrRNA, Cas Enzymes and Sensing), End User (Hospitals, Diagnostic Centers, Biotechnology Companies, Academic and Research Institutes and Others), Distribution Channel (Direct Tender, Retail Sales) Country (Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
CRISPR is clustered regularly interspaced short palindromic repeats, is a tool for genome editing, meaning it allows researchers to easily alter DNA sequences and modify gene function. It has many potential applications, including correcting genetic defects, treating and preventing the spread of diseases. CRISPR-based diagnostics have been used for a wide range of biomedical applications, such as the sensing of nucleic-acid-based biomarkers of infectious and non-infectious diseases and for detection of genetic diseases. The assay kits in CRISPR is made up of two components: a protein called Cas9 and a guide RNA, a string of nucleic acid molecules with a certain genetic code.
This CRISPR-Cas9 system has been modified for use in mammalian cells. By introducing a guide sequence (sgRNA) specific for our gene of interest, we can either knock-out specific genes through introducing frame shift mutations via Non-Homologous End Joining (NHEJ), or generate knock-in mutations.
CRISPR-Cas 9 system have extended the scope of diagnostics and services for use in gene and cell therapies. Pharmaceutical companies are investing heavily in R&D to develop new products, with a surge of gene and cell therapy agents now entering early development. The market players are investing would allow to achieve the goal of producing safe and effective treatments for patients who are in serious need.
Market Segmentation:
The Asia-Pacific CRISPR gene detection and diagnostic market is categorized into six segments: class, products and services, application, workflow, end user, and distribution channel.
On the basis of class, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into class 1- multiple effector proteins and class 2 -single crRNA-binding protein
On the basis of products and services, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into products and services
On the basis of application, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into biomedical diagnostics, genome engineering, drug discovery, agricultural applications and others
On the basis of workflow, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into sample preparation, pre-amplification, crRNA, Cas enzymes and sensing
On the basis of end user, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into hospitals, diagnostic centers, biotechnology companies, academic and research institutes and others
On the basis of distribution channel, the Asia-Pacific CRISPR gene detection and diagnostic market is segmented into direct tenders, retail sales
Market Players
Some of the major players operating in the market are:
GenScript
Takara Bio Inc.
OriGene Technologies, Inc.
Agilent Technologies, Inc.
Synthego
Merck KGaA
Integrated DNA Technologies, Inc. (A subsidiary of Danaher)
Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET 25
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 27
1.6 MARKETS COVERED 28
2 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 DBMR TRIPOD DATA VALIDATION MODEL 34
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.6 MULTIVARIATE MODELLING 38
2.7 CLASS SEGMENT LIFELINE CURVE 38
2.8 DBMR MARKET POSITION GRID 39
2.9 VENDOR SHARE ANALYSIS 41
2.10 MARKET END USER COVERAGE GRID 42
2.11 SECONDARY SOURCES 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 48
4.1 PESTEL 49
4.2 PORTER'S FIVE FORCES MODEL 50
5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE) 51
6 EPIDEMIOLOGY 54
7 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO 55
8 PIPELINE ANALYSIS FOR ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS 57
9 MARKET OVERVIEW 58
9.1 DRIVERS 60
9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 60
9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT 62
9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS 63
9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC 63
9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS 63
9.2 RESTRAINTS 64
9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS 64
9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS 64
9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH 65
9.2.4 AVAILABILITY OF ALTERNATIVES 65
9.3 OPPORTUNITIES 65
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 65
9.3.2 RISE IN HEALTHCARE EXPENDITURE 66
9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS 66
9.4 CHALLENGES 67
9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS 67
9.4.2 STRINGENT REGULATIONS 67
10 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS 69
10.1 OVERVIEW 70
10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN 73
10.2.1 BIOMEDICAL DIAGNOSTICS 74
10.2.2 AGRICULTURAL APPLICATIONS 74
10.2.3 GENOME ENGINEERING 74
10.2.4 DRUG DISCOVERY 74
10.2.5 OTHERS 74
10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS 75
11 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES 76
11.1 OVERVIEW 77
11.2 PRODUCTS 80
11.2.1 ASSAY KITS 81
11.2.1.1 SGRNA KIT 81
11.2.1.2 GENOMIC DETECTION KIT 81
11.2.1.3 OTHERS 82
11.2.2 PROTEINS 82
11.2.2.1 CAS9 82
11.2.2.2 CPF1 82
11.2.2.3 OTHERS 82
11.2.3 PLASMID AND VECTOR 83
11.2.4 LIBRARY 83
11.2.5 CONTROL KITS 83
11.2.6 DELIVERY SYSTEM PRODUCTS 83
11.2.7 DESIGN TOOLS 83
11.2.8 GENOMIC RNA 83
11.2.9 HDR BLOCKERS 83
11.2.9.1 AZIDOTHYMIDINE 84
11.2.9.2 TRIFLUOROTHYMIDINE 84
11.2.9.3 OTHERS 84
11.2.9.4 OTHERS 84
11.3 SERVICES 84
11.3.1 G-RNA DESIGN 85
11.3.2 CELL LINE ENGINEERING 85
11.3.3 MICROBIAL GENE EDITING 85
11.3.4 DNA SYNTHESIS 86
11.3.5 OTHERS 86
12 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION 87
12.1 OVERVIEW 88
12.2 BIOMEDICAL DIAGNOSTICS 91
12.2.1 CANCER 92
12.2.2 BLOOD DISORDERS 92
12.2.3 HEREDITARY DISORDERS 92
12.2.4 MUSCULAR DYSTROPHY 92
12.2.5 AIDS 92
12.2.6 NEURODEGENERATIVE CONDITION 92
12.2.7 OTHERS 93
12.3 AGRICULTURAL APPLICATIONS 93
12.4 GENOME ENGINEERING 93
12.4.1 CELL LINE ENGINEERING 94
12.4.2 HUMAN STEM CELLS 94
12.5 DRUG DISCOVERY 95
12.6 OTHERS 96
13 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW 97
13.1 OVERVIEW 98
13.2 CRRNA 101
13.3 CAS ENZYME 101
13.4 PRE-AMPLIFICATION 102
13.4.1 PCR 103
13.4.2 LAMP 103
13.4.3 RPA 103
13.5 SAMPLE PREPARATION 103
13.6 SENSING 104
13.6.1 FLUORESCENT PROBES 105
13.6.2 COLORIMETRIC 105
14 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER 106
14.1 OVERVIEW 107
14.2 BIOTECHNOLOGY COMPANIES 110
14.3 ACADEMIC AND RESEARCH INSTITUTES 111
14.4 DIAGNOSTIC CENTERS 112
14.5 HOSPITALS 113
14.6 OTHERS 114
15 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 115
15.1 OVERVIEW 116
15.2 DIRECT TENDER 120
15.3 RETAIL SALES 121
16 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION 122
16.1 ASIA-PACIFIC 123
16.1.1 CHINA 132
16.1.2 JAPAN 137
16.1.3 INDIA 142
16.1.4 SOUTH KOREA 147
16.1.5 AUSTRALIA 152
16.1.6 SINGAPORE 157
16.1.7 THAILAND 162
16.1.8 PHILIPPINES 167
16.1.9 MALAYSIA 172
16.1.10 INDONESIA 177
16.1.11 REST OF ASIA-PACIFIC 182
17 ASIA PACIFIC CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE 183
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 183
18 SWOT ANALYSIS 184
19 COMPANY PROFILE 185
19.1 THERMO FISHER SCIENTIFIC INC. 185
19.1.1 COMPANY SNAPSHOT 185
19.1.2 REVENUE ANALYSIS 185
19.1.3 COMPANY SHARE ANALYSIS 186
19.1.4 PRODUCT PORTFOLIO 186
19.1.5 RECENT DEVELOPMENTS 187
19.2 MERCK KGA 188
19.2.1 COMPANY SNAPSHOT 188
19.2.2 REVENUE ANALYSIS 188
19.2.3 COMPANY SHARE ANALYSIS 189
19.2.4 PRODUCT PORTFOLIO 189
19.2.5 RECENT DEVELOPMENTS 190
19.3 AGILENT TECHNILOGIES, INC 192
19.3.1 COMPANY SNAPSHOT 192
19.3.2 REVENUE ANALYSIS 192
19.3.3 COMPANY SHARE ANALYSIS 193
19.3.4 PRODUCT PORTFOLIO 193
19.3.5 RECENT DEVELOPMENT 194
19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER) 195
19.4.1 COMPANY SNAPSHOT 195
19.4.2 REVENUE ANALYSIS 195
19.4.3 COMPANY SHARE ANALYSIS 196
19.4.4 PRODUCT PORTFOLIO 196
19.4.5 RECENT DEVELOPMENTS 197
19.5 GENSCRIPT 198
19.5.1 COMPANY SNAPSHOT 198
19.5.2 REVENUE ANALYSIS 198
19.5.3 COMPANY SHARE ANALYSIS 199
19.5.4 PRODUCT PORTFOLIO 199
19.5.5 RECENT DEVELOPMENT 200
19.6 10 X GENOMICS 201
19.6.1 COMPANY SNAPSHOT 201
19.6.2 REVENUE ANALYSIS 201
19.6.3 PRODUCT PORTFOLIO 202
19.6.4 RECENT DEVELOPMENTS 202
19.7 APPLIED STEM CELL 203
19.7.1 COMPANY SNAPSHOT 203
19.7.2 PRODUCT PORTFOLIO 203
19.7.3 RECENT DEVELOPMENT 203
19.8 ADDGENE 204
19.8.1 COMPANY SNAPSHOT 204
19.8.2 PRODUCT PORTFOLIO 204
19.8.3 RECENT DEVELOPMENT 204
19.9 BIOVISION INC. 205
19.9.1 COMPANY SNAPSHOT 205
19.9.2 PRODUCT PORTFOLIO 205
19.9.3 RECENT DEVELOPMENT 206
19.10 CELLECTA, INC 207
19.10.1 COMPANY SNAPSHOT 207
19.10.2 PRODUCT PORTFOLIO 207
19.10.3 RECENT DEVELOPMENTS 208
19.11 CAS TAG BIOSCIENCES 209
19.11.1 COMPANY SNAPSHOT 209
19.11.2 PRODUCT PORTFOLIO 209
19.11.3 RECENT DEVELOPMENT 209
19.12 GENECOPOEIA, INC. 210
19.12.1 COMPANY SNAPSHOT 210
19.12.2 PRODUCT PORTFOLIO 210
19.12.3 RECENT DEVELOPMENT 210
19.13 HORIZON DISCOVERY LTD 211
19.13.1 COMPANY SNAPSHOT 211
19.13.2 PRODUCT PORTFOLIO 211
19.13.3 RECENT DEVELOPMENTS 212
19.14 HERA BIOLABS 213
19.14.1 COMPANY SNAPSHOT 213
19.14.2 PRODUCT PORTFOLIO 213
19.14.3 RECENT DEVELOPMENT 214
19.15 NEW ENGLAND BIOLABS 215
19.15.1 COMPANY SNAPSHOT 215
19.15.2 PRODUCT PORTFOLIO 215
19.15.3 RECENT DEVELOPMENTS 216
19.16 ORIGENE TECHNOLOGIES, INC. 217
19.16.1 COMPANY SNAPSHOT 217
19.16.2 PRODUCT PORTFOLIO 217
19.16.3 RECENT DEVELOPMENT 218
19.17 SYNTHEGO 219
19.17.1 COMPANY SNAPSHOT 219
19.17.2 PRODUCT PORTFOLIO 219
19.17.3 RECENT DEVELOPMENTS 219
19.18 TAKARA BIO INC. 221
19.18.1 COMPANY SNAPSHOT 221
19.18.2 REVENUE ANALYSIS 221
19.18.3 PRODUCT PORTFOLIO 222
19.18.4 RECENT DEVELOPMENT 222
19.19 TOOLGEN, INC. 223
19.19.1 COMPANY SNAPSHOT 223
19.19.2 PRODUCT PORTFOLIO 223
19.19.3 RECENT DEVELOPMENT 223
20 QUESTIONNAIRE 224
21 RELATED REPORTS 227
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
